Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CLSPN antisense RNA 1 (CLSPN-AS1) is a long non-coding antisense RNA transcribed opposite the CLSPN gene locus. While antisense RNAs can theoretically regulate expression of their sense gene via various mechanisms, there is currently no direct evidence describing the biological functions, disease associations, drug interactions, or clinical relevance of CLSPN-AS1. Nearly all available scientific and therapeutic data focus on the CLSPN gene and its encoded protein Claspin—a checkpoint mediator critical for DNA replication fidelity and cell cycle arrest following DNA damage[1][3][4][6]. Therefore, CLSPN-AS1 is not a recognized direct therapeutic target, and it is potentially an incorrect target designation for most clinical or research applications. For information related to DNA damage response, cell cycle checkpoint, and therapeutic targeting, consult references on CLSPN (Claspin) and its protein product. Key note: If your intention is to target the DNA damage checkpoint pathway, focus on CLSPN and its protein product (Claspin) rather than the antisense RNA[1][3][4][6].
None known
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CLSPN antisense RNA 1 (CLSPN-AS1).